Download PDF
Semin Respir Crit Care Med 2017; 38(02): 185-190
DOI: 10.1055/s-0037-1602243
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Interstitial Lung Disease in Women of Child-Bearing Age

Ruben Mylvaganam
1   Division of Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
,
Sakshi Dua
1   Division of Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
,
Catherine Nelson-Piercy
2   Women's Health Academic Centre, St. Thomas' Hospital, London, United Kingdom
,
Aditi Mathur
1   Division of Pulmonary and Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2017 (online)

    Permissions and Reprints

Abstract

Interstitial lung disease (ILD) is an inflammatory and fibrotic infiltrative process of the lung that is often associated with collagen vascular disease in women. Untreated, it results in collagen deposition in the lung interstitium that can lead to a slow suffocating death. Pregnancy planning is often not discussed with women who have ILD due to concerns about potentially aggravating the disease process, or due to lack of knowledge about the safety of medications used to treat ILD. With improved understanding of the pathophysiology of both autoimmune disease and ILD, it has become clear that safe, planned pregnancies are possible in most women with ILD. In this article, our aim is to review diagnosis, treatment, and disease course of ILD in women who are planning a pregnancy or are pregnant. Better understanding of the disease process and knowledge of safe treatments will likely lead to improved pregnancy planning in women with ILD.

Keywords

interstitial lung disease - pregnancy - connective tissue disease - collagen vascular disease - teratogenic
 

  • References

  • 1 Crapo RO. Normal cardiopulmonary physiology during pregnancy. Clin Obstet Gynecol 1996; 39 (01) 3-16
    CrossrefPubMedGoogle Scholar
  • 2 Chesnutt AN. Physiology of normal pregnancy. Crit Care Clin 2004; 20 (04) 609-615
    CrossrefPubMedGoogle Scholar
  • 3 Pereira A, Krieger BP. Pulmonary complications of pregnancy. Clin Chest Med 2004; 25 (02) 299-310
    CrossrefPubMedGoogle Scholar
  • 4 McCormack MC, Wise RA. Respiratory physiology in pregnancy. In: Bourjeily G, Rosene-Montella K. , eds. Pulmonary Problems in Pregnancy. New York, NY: Springer; 2009: 19-26
    CrossrefGoogle Scholar
  • 5 Krumholz RA, Echt CR, Ross JC. Pulmonary diffusing capacity, capillary blood volume, lung volumes, and mechanics of ventilation in early and late pregnancy. J Lab Clin Med 1964; 63: 648-655
    PubMedGoogle Scholar
  • 6 Milne JA, Mills RJ, Coutts JR, Macnaughton MC, Moran F, Pack AI. The effect of human pregnancy on the pulmonary transfer factor for carbon monoxide as measured by the single-breath method. Clin Sci Mol Med 1977; 53 (03) 271-276
    PubMedGoogle Scholar
  • 7 Gazioglu K, Kaltreider NL, Rosen M, Yu PN. Pulmonary function during pregnancy in normal women and in patients with cardiopulmonary disease. Thorax 1970; 25 (04) 445-450
    CrossrefPubMedGoogle Scholar
  • 8 Boros PW, Franczuk M, Wesolowski S. Value of spirometry in detecting volume restriction in interstitial lung disease patients. Spirometry in interstitial lung diseases. Respiration 2004; 71 (04) 374-379
    CrossrefPubMedGoogle Scholar
  • 9 Bradley B, Branley HM, Egan JJ. , et al; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 (Suppl. 05) v1-v58
    CrossrefPubMedGoogle Scholar
  • 10 van den Broe NR, Letsky EA. Pregnancy and the erythrocyte sedimentation rate. BJOG 2001; 108 (11) 1164-1167
    PubMedGoogle Scholar
  • 11 Flaherty KR, Andrei A-C, Murray S. , et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006; 174 (07) 803-809
    CrossrefPubMedGoogle Scholar
  • 12 Gjelsteen AC, Ching BH, Meyermann MW. , et al. CT, MRI, PET, PET/CT, and ultrasound in the evaluation of obstetric and gynecologic patients. Surg Clin North Am 2008; 88 (02) 361-390 , vii
    CrossrefPubMedGoogle Scholar
  • 13 Patel SJ, Reede DL, Katz DS, Subramaniam R, Amorosa JK. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. Radiographics 2007; 27 (06) 1705-1722
    CrossrefPubMedGoogle Scholar
  • 14 Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 2002; 19 (05) 794-796
    CrossrefPubMedGoogle Scholar
  • 15 Lee H-K, Kim DS, Yoo B. , et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127 (06) 2019-2027
    CrossrefPubMedGoogle Scholar
  • 16 Douglas WW, Tazelaar HD, Hartman TE. , et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164 (07) 1182-1185
    CrossrefPubMedGoogle Scholar
  • 17 Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130 (05) 1489-1495
    CrossrefPubMedGoogle Scholar
  • 18 Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013; 22 (127) 6-19
    CrossrefPubMedGoogle Scholar
  • 19 Lapinsky SE, Tram C, Mehta S, Maxwell CV. Restrictive lung disease in pregnancy. Chest 2014; 145 (02) 394-398
    CrossrefPubMedGoogle Scholar
  • 20 Boggess KA, Easterling TR, Raghu G. Management and outcome of pregnant women with interstitial and restrictive lung disease. Am J Obstet Gynecol 1995; 173 (04) 1007-1014
    CrossrefPubMedGoogle Scholar
  • 21 Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 2016; 15 (10) 955-963
    CrossrefPubMedGoogle Scholar
  • 22 Pinsky L, DiGeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science 1965; 147 (3656): 402-403
    CrossrefPubMedGoogle Scholar
  • 23 Walker BE. Induction of cleft palate in rats with antiinflammatory drugs. Teratology 1971; 4 (01) 39-42
    CrossrefPubMedGoogle Scholar
  • 24 Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183 (07) 796-804
    CrossrefPubMedGoogle Scholar
  • 25 Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202 (4366): 436-438
    CrossrefPubMedGoogle Scholar
  • 26 Pirson Y, Van Lierde M, Ghysen J, Squifflet JP, Alexandre GP, van Ypersele de Strihou C. Retardation of fetal growth in patients receiving immunosuppressive therapy. N Engl J Med 1985; 313 (05) 328
    CrossrefPubMedGoogle Scholar
  • 27 Baldwin C, Avina-Zubieta A, Rai SK, Carruthers E, De Vera MA. Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations. Clin Exp Rheumatol 2016; 34 (02) 172-183
    PubMedGoogle Scholar
  • 28 Hazes JM, Coulie PG, Geenen V. , et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford) 2011; 50 (11) 1955-1968
    CrossrefPubMedGoogle Scholar
  • 29 Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19 (01) 15-22
    CrossrefPubMedGoogle Scholar
  • 30 Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 2011; 71 (15) 1973-1987
    CrossrefPubMedGoogle Scholar
  • 31 Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol 2004; 18 (02) 219-230
    CrossrefPubMedGoogle Scholar
  • 32 Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus 2016; 25 (09) 973-979
    CrossrefPubMedGoogle Scholar
  • 33 Sau A, Clarke S, Bass J, Kaiser A, Marinaki A, Nelson-Piercy C. Azathioprine and breastfeeding: is it safe?. BJOG 2007; 114 (04) 498-501
    CrossrefPubMedGoogle Scholar
  • 34 Nelson-Piercy C, Agarwal S, Lams B. Lesson of the month: selective use of cyclophosphamide in pregnancy for severe autoimmune respiratory disease. Thorax 2016; 71 (07) 667-668
    CrossrefPubMedGoogle Scholar
  • 35 Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008; 7 (03) 219-222
    CrossrefPubMedGoogle Scholar
  • 36 Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35 (02) 112-121
    CrossrefPubMedGoogle Scholar
  • 37 Ylikorkala O, Sjöstedt E, Järvinen PA, Tikkanen R, Raines T. Trimethoprim-sulfonamide combination administered orally and intravaginally in the first trimester of pregnancy: its absorption into serum and transfer to amniotic fluid. Acta Obstet Gynecol Scand 1973; 52 (03) 229-234
    CrossrefPubMedGoogle Scholar
  • 38 Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343 (22) 1608-1614
    CrossrefPubMedGoogle Scholar
  • 39 Kennedy D, Koren G. Identifying women who might benefit from higher doses of folic acid in pregnancy. Can Fam Physician 2012; 58 (04) 394-397
    PubMedGoogle Scholar
  • 40 Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2015; 74 (10) 1836-1841
    CrossrefPubMedGoogle Scholar
  • 41 Saar P, Hermann W, Müller-Ladner U. Connective tissue diseases and pregnancy. Rheumatology (Oxford) 2006; 45 (03) (Suppl. 03) iii30-iii32
    PubMedGoogle Scholar
  • 42 Götestam Skorpen C, Hoeltzenbein M, Tincani A. , et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75 (05) 795-810
    CrossrefPubMedGoogle Scholar